Keensight Capital Acquires Inke from Neuraxpharm
May 1, 2023
Keensight Capital has signed a binding agreement to acquire Inke, a Spain-based specialist developer and manufacturer of inhalation active pharmaceutical ingredients (APIs), from Neuraxpharm Group; financial terms were not disclosed and the deal is expected to close in May 2023. Neuraxpharm divested Inke to sharpen its focus on CNS therapies, while Keensight will support Inke's management team to expand its footprint, broaden its offering and grow its product portfolio.
- Buyers
- Keensight Capital
- Targets
- Inke
- Sellers
- Neuraxpharm Group
- Industry
- Pharmaceuticals
- Location
- Catalonia, Spain
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.